{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:38:28Z","timestamp":1791805108671,"version":"4.3.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"DOI":"10.1038\/s41409-026-03044-3","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:23:15Z","timestamp":1790245395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article"],"prefix":"10.1038","author":[{"given":"Abdulrahman","family":"Nasiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-3865","authenticated-orcid":false,"given":"Riad","family":"El Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-4889","authenticated-orcid":false,"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6138-8112","authenticated-orcid":false,"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-7806","authenticated-orcid":false,"given":"Jurgen","family":"Kuball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4522","authenticated-orcid":false,"given":"Marcos","family":"De Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1128-0445","authenticated-orcid":false,"given":"Muhammad Bilal","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhatullah","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2532","authenticated-orcid":false,"given":"Ibrahim N.","family":"Muhsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-8579","authenticated-orcid":false,"given":"Daniel","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard T.","family":"Greinix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6722-0065","authenticated-orcid":false,"given":"Anna","family":"Ossami Saidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4552-0109","authenticated-orcid":false,"given":"Mohammad","family":"Alhomoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulwahab","family":"Albabtain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-483X","authenticated-orcid":false,"given":"Helen","family":"Baldomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1899-7186","authenticated-orcid":false,"given":"Shahrukh","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8167-2989","authenticated-orcid":false,"given":"Lorenz","family":"Thurner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3599-8099","authenticated-orcid":false,"given":"Nina","family":"Worel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Seber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8048-2892","authenticated-orcid":false,"given":"Sebastian","family":"Galeano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-7385","authenticated-orcid":false,"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-3491","authenticated-orcid":false,"given":"Raheel","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Osman","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Rondelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-3476","authenticated-orcid":false,"given":"John A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4737-1103","authenticated-orcid":false,"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4368-2502","authenticated-orcid":false,"given":"Mickey","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-7370","authenticated-orcid":false,"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"3044_CR1","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135. https:\/\/doi.org\/10.1126\/science.aar6711.","journal-title":"Science"},{"key":"3044_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"3044_CR3","unstructured":"U.S. Food and Drug Administration. FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma."},{"key":"3044_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"key":"3044_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"3044_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jtct.2025.05.012","volume":"31","author":"SO Ahmed","year":"2025","unstructured":"Ahmed SO, El Fakih R, Kharfan-Dabaja MA, Syed F, Mufti G, Chabannon C, et al. Setting up a chimeric antigen receptor T-cell therapy program: a framework for delivery from the Worldwide Network for Blood & Marrow Transplantation. Transpl Cell Ther. 2025;31:533\u201343. https:\/\/doi.org\/10.1016\/j.jtct.2025.05.012.","journal-title":"Transpl Cell Ther"},{"key":"3044_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10:210 https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Signal Transduct Target Ther"},{"key":"3044_CR8","first-page":"S64","volume":"32","author":"S Dahiya","year":"2026","unstructured":"Dahiya S, Ulrickson ML, Yared JA, Reagan PM, Voorhees T, Reshef R, et al. A phase 1 study of KITE-753 or KITE-363 in patients with relapsed\/refractory B-cell lymphoma: initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363. Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther. 2026;32:S64\u2013S65.","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"key":"3044_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood-2025-811","volume":"146","author":"P Barba","year":"2025","unstructured":"Barba P, Rambaldi A, Boissel N, Doki N, Blaise D, Ciceri F, et al. Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed\/Refractory B-cell acute lymphoblastic leukemia (r\/r B-ALL). Blood. 2025;146:811.","journal-title":"Blood"},{"key":"3044_CR10","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/frtra.2023.1238535","volume":"2","author":"M Shah","year":"2023","unstructured":"Shah M, Krull A, Odonnell L, de Lima MJ, Bezerra E. Promises and challenges of a decentralized CAR T-cell manufacturing model. Front Transplant. 2023;2:2023 https:\/\/doi.org\/10.3389\/frtra.2023.1238535.","journal-title":"Front Transplant"},{"key":"3044_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncol. 2016;3:16015. https:\/\/doi.org\/10.1038\/mto.2016.15.","journal-title":"Mol Ther Oncol"},{"key":"3044_CR12","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.ymthe.2019.06.001","volume":"27","author":"PJ Hanley","year":"2019","unstructured":"Hanley PJ. Fresh versus frozen: effects of cryopreservation on CAR T cells. Mol Ther. 2019;27:1213\u20134. https:\/\/doi.org\/10.1016\/j.ymthe.2019.06.001.","journal-title":"Mol Ther"},{"key":"3044_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1762453","volume":"17","author":"K Makni-Maalej","year":"2026","unstructured":"Makni-Maalej K, Alotaibi SM, Fernandes Q, Ahmed SO, Mestiri S, Bougarn S, et al. Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies. Front Immunol. 2026;17:1762453. https:\/\/doi.org\/10.3389\/fimmu.2026.1762453.","journal-title":"Front Immunol"},{"key":"3044_CR14","unstructured":"European Parliament and Council of the European Union. Regulation (EC) No 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and Regulation (EC) No 726\/2004. Off J Eur Union. 2007;L324:121\u201337."},{"key":"3044_CR15","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2025-2406","volume":"146","author":"F Syed","year":"2025","unstructured":"Syed F, Warda W, Alqudairy H, Alrasheed N, Ahmed S, Alsuliman A, et al. Disrupting the global CAR T paradigm from the Middle East: ultra-fast swift CAR T and scalable point-of-care manufacturing of autologous CAR T cells for hematologic malignancies. Blood. 2025;146:2406\u20132406. https:\/\/doi.org\/10.1182\/blood-2025-2406.","journal-title":"Blood"},{"key":"3044_CR16","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1182\/bloodadvances.2025016181","volume":"9","author":"F Del Bufalo","year":"2025","unstructured":"Del Bufalo F, Becilli M, Rosignoli C, Merli P, Algeri M, Pagliara D, et al. Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed\/refractory or in very-high-risk first relapse. Blood Adv. 2025;9:5091\u2013102. https:\/\/doi.org\/10.1182\/bloodadvances.2025016181.","journal-title":"Blood Adv"},{"key":"3044_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200889","volume":"32","author":"S Luanpitpong","year":"2024","unstructured":"Luanpitpong S, Klaihmon P, Janan M, Kungwankiattichai S, Owattanapanich W, Kunacheewa C, et al. Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: experiences of an academic in Thailand. Mol Ther Oncol. 2024;32:200889. https:\/\/doi.org\/10.1016\/j.omton.2024.200889.","journal-title":"Mol Ther Oncol"},{"key":"3044_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101114","volume":"31","author":"N Francis","year":"2023","unstructured":"Francis N, Braun M, Neagle S, Peiffer S, Bohn A, Rosenthal A, et al. Development of an automated manufacturing process for large-scale production of autologous T cell therapies. Mol Ther Methods Clin Dev. 2023;31:101114. https:\/\/doi.org\/10.1016\/j.omtm.2023.101114.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3044_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jcyt.2024.03.003","volume":"26","author":"HW Song","year":"2024","unstructured":"Song HW, Prochazkova M, Shao L, Traynor R, Underwood S, Black M, et al. CAR-T cell expansion platforms yield distinct T cell differentiation states. Cytotherapy. 2024;26:757\u201368. https:\/\/doi.org\/10.1016\/j.jcyt.2024.03.003.","journal-title":"Cytotherapy"},{"key":"3044_CR20","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jcyt.2023.07.012","volume":"25","author":"N Trainor","year":"2023","unstructured":"Trainor N, Purpura KA, Middleton K, Fargo K, Hails L, Vicentini-Hogan M, et al. Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform. Cytotherapy. 2023;25:1349\u201360. https:\/\/doi.org\/10.1016\/j.jcyt.2023.07.012.","journal-title":"Cytotherapy"},{"key":"3044_CR21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3389\/fimmu.2020.01941","volume":"11","author":"Z Jackson","year":"2020","unstructured":"Jackson Z, Roe A, Sharma AA, Lopes F, Talla A, Kleinsorge-Block S, et al. Automated manufacture of autologous CD19 CAR-T cells for treatment of non-Hodgkin lymphoma. Front Immunol. 2020;11:1941. https:\/\/doi.org\/10.3389\/fimmu.2020.01941.","journal-title":"Front Immunol"},{"key":"3044_CR22","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1182\/blood-2024-207532","volume":"144","author":"S Vasu","year":"2024","unstructured":"Vasu S, Bezerra E, Denlinger N, Szuminski N, Schneider D, Dash P, et al. Initial results of a first-in-human, phase I study point-of-care manufacturing of trispecific CAR-T cells targeting CD19\/20\/22 in B-cell malignancies. Blood. 2024;144:2078.","journal-title":"Blood"},{"key":"3044_CR23","unstructured":"Children\u2019s Hospital of Philadelphia Launches Global Partnership to Establish a CAR\u2011T Therapy Program in Brazil. Children\u2019s Hospital of Philadelphia, 2024. www.chop.edu\/news\/childrens-hospital-philadelphia-launches-global-partnership-establish-car-t-therapy-program. Press release"},{"key":"3044_CR24","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","volume":"29","author":"V Ort\u00edz-Maldonado","year":"2021","unstructured":"Ort\u00edz-Maldonado V, Rives S, Castell\u00e0 M, Alonso-Saladrigues A, Ben\u00edtez-Ribas D, Caballero-Ba\u00f1os M, et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19(+) relapsed\/refractory malignancies. Mol Ther. 2021;29:636\u201344. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.027.","journal-title":"Mol Ther"},{"key":"3044_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","volume":"24","author":"A Oliver-Cald\u00e9s","year":"2023","unstructured":"Oliver-Cald\u00e9s A, Gonz\u00e1lez-Calle V, Caba\u00f1as V, Espa\u00f1ol-Rego M, Rodr\u00edguez-Otero P, Reguera JL, et al. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol. 2023;24:913\u201324.","journal-title":"Lancet Oncol"},{"key":"3044_CR26","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S Cordoba","year":"2021","unstructured":"Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021;27:1797\u2013805. https:\/\/doi.org\/10.1038\/s41591-021-01497-1.","journal-title":"Nat Med"},{"key":"3044_CR27","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388:1284\u201395.","journal-title":"N Engl J Med"},{"key":"3044_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jama.2025.21721","volume":"335","author":"U Mahat","year":"2026","unstructured":"Mahat U, Das A, Kumar V, Prasad V. Advancing CAR T-cell therapy: evidence-based trial design for chimeric antigen receptor T-cell therapy in oncology. JAMA. 2026;335:21\u201324. https:\/\/doi.org\/10.1001\/jama.2025.21721.","journal-title":"JAMA"},{"key":"3044_CR29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","volume":"28","author":"S Prommersberger","year":"2021","unstructured":"Prommersberger S, Reiser M, Beckmann J, Danhof S, Amberger M, Quade-Lyssy P, et al. CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene Ther. 2021;28:560\u201371. https:\/\/doi.org\/10.1038\/s41434-021-00254-w.","journal-title":"Gene Ther"},{"key":"3044_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06400-x","volume":"23","author":"D Gupta","year":"2025","unstructured":"Gupta D, Shaz B. Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility. J Transl Med. 2025;23:507. https:\/\/doi.org\/10.1186\/s12967-025-06400-x.","journal-title":"J Transl Med"},{"key":"3044_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jcyt.2024.02.025","volume":"26","author":"E Malakhova","year":"2024","unstructured":"Malakhova E, Pershin D, Kulakovskaya E, Vedmedskaia V, Fadeeva M, Lodoeva O, et al. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration. Cytotherapy. 2024;26:567\u201378. https:\/\/doi.org\/10.1016\/j.jcyt.2024.02.025.","journal-title":"Cytotherapy"},{"key":"3044_CR32","doi-asserted-by":"publisher","unstructured":"Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers 2023;15. https:\/\/doi.org\/10.3390\/cancers15041003","DOI":"10.3390\/cancers15041003"},{"key":"3044_CR33","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s12672-025-03282-9","volume":"16","author":"L Yan","year":"2025","unstructured":"Yan L, Duan B, Sun P, Wang T, Wang T, Jiang S, et al. CAR-T cell therapy in China: innovations, challenges, and strategic pathways. Discov Oncol. 2025;16:1593 https:\/\/doi.org\/10.1007\/s12672-025-03282-9.","journal-title":"Discov Oncol"},{"key":"3044_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03938-0","volume":"25","author":"J Zhu","year":"2025","unstructured":"Zhu J, Zhou J, Tang Y, Huang R, Lu C, Qian K, et al. Advancements and challenges in CAR-T cell therapy for solid tumors: a comprehensive review of antigen targets, strategies, and future directions. Cancer Cell Int. 2025;25:313. https:\/\/doi.org\/10.1186\/s12935-025-03938-0.","journal-title":"Cancer Cell Int"},{"key":"3044_CR35","doi-asserted-by":"publisher","unstructured":"Nguyen LT, Nguyen DD, Bach QK, Dao LTM, Phan TTK, Nguyen HP et al. Outcomes of point-of-care manufactured CAR T cell therapy for B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in Vietnam. Mol Ther Oncol 2026;34. https:\/\/doi.org\/10.1016\/j.omton.2026.201156","DOI":"10.1016\/j.omton.2026.201156"},{"key":"3044_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/d41586-024-00809-y","volume":"627","author":"S Mallapaty","year":"2024","unstructured":"Mallapaty S. Cutting-edge CAR-T cancer therapy is now made in India - at one-tenth the cost. Nature. 2024;627:709\u201310. https:\/\/doi.org\/10.1038\/d41586-024-00809-y.","journal-title":"Nature"},{"key":"3044_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009611","volume":"12","author":"S Gautam","year":"2024","unstructured":"Gautam S, Gautam B, Shilpakar R, K C S, Kurmi OP. CAR-T cell therapy in developing countries: How long should we wait? J Immunother Cancer. 2024;12:e009611. https:\/\/doi.org\/10.1136\/jitc-2024-009611.","journal-title":"J Immunother Cancer"},{"key":"3044_CR38","unstructured":"US-based Caring Cross and Burjeel Holdings Partner to Bring Revolutionary CAR\u2011T Therapy to MENA Through Local Manufacturing. Caring Cross. 2025. https:\/\/caringcross.org\/press\/us-based-caring-cross-and-burjeel-holdings-partner-to-bring-revolutionary-car-t-therapy-to-mena-through-local-manufacturing\/. Press release"},{"key":"3044_CR39","unstructured":"IMPACT Receives International Grant from ScaleReady to Advance CAR\u2011T Cell Therapy Project. IMPACT Center, 2025. https:\/\/centerimpact.cl\/impact-receives-international-grant-from-scaleready-to-advance-car-t-cell-therapy-project\/. Press release"},{"key":"3044_CR40","doi-asserted-by":"crossref","unstructured":"Boissel N, Ciceri F. Bridging chemotherapy: adult acute lymphoblastic leukaemia. In: Kr\u00f6ger N, Gribben J, Chabannon C (eds). The EBMT\/EHA CAR-T cell Handbook. Springer: Cham, 2022.","DOI":"10.1007\/978-3-030-94353-0_20"},{"key":"3044_CR41","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B-cell ALL patients. J Clin Investig. 2016;126:2123\u201338. https:\/\/doi.org\/10.1172\/JCI85309.","journal-title":"J Clin Investig"},{"key":"3044_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1182\/blood-2024-206596","volume":"144","author":"C Deng","year":"2024","unstructured":"Deng C, Caimi PF, Farooq U, Idippily N, Giraudo MF, Reese JS, et al. Phase I study results of UF-Kure19, a CAR-T product manufactured in less than 1 Day, in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma. Blood. 2024;144:94.","journal-title":"Blood"},{"key":"3044_CR43","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fimmu.2022.1007042","volume":"13","author":"J Abraham-Miranda","year":"2022","unstructured":"Abraham-Miranda J, Menges M, Atkins R, Mattie M, Kanska J, Turner J, et al. CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production. Front Immunol. 2022;13:2022. https:\/\/doi.org\/10.3389\/fimmu.2022.1007042.","journal-title":"Front Immunol"},{"key":"3044_CR44","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.ymthe.2019.05.015","volume":"27","author":"SR Panch","year":"2019","unstructured":"Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, et al. Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics. Mol Ther. 2019;27:1275\u201385.","journal-title":"Mol Ther"},{"key":"3044_CR45","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell\u2013like properties. Nat Med. 2011;17:1290\u20137. https:\/\/doi.org\/10.1038\/nm.2446.","journal-title":"Nat Med"},{"key":"3044_CR46","doi-asserted-by":"publisher","unstructured":"Caimi PF, Reese J, Otegbeye F, Schneider D, Chamoun K, Boughan KM et al. Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain. J Clin Oncol;37:2539. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2539.","DOI":"10.1200\/JCO.2019.37.15_suppl.2539"},{"key":"3044_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103138","volume":"81","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Caimi PF, Reese JS, Goparaju K, di Trani M, Ritchey J, et al. Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial. EClinicalMedicine. 2025;81:103138. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103138.","journal-title":"EClinicalMedicine"},{"key":"3044_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27312-6","volume":"12","author":"M Maschan","year":"2021","unstructured":"Maschan M, Caimi PF, Reese-Koc J, Sanchez GP, Sharma AA, Molostova O, et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat Commun. 2021;12:7200. https:\/\/doi.org\/10.1038\/s41467-021-27312-6.","journal-title":"Nat Commun"},{"key":"3044_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jtct.2022.02.017","volume":"28","author":"M Kedmi","year":"2022","unstructured":"Kedmi M, Shouval R, Fried S, Bomze D, Fein J, Cohen Z, et al. Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. Transpl Cell Ther. 2022;28:251\u20137. https:\/\/doi.org\/10.1016\/j.jtct.2022.02.017.","journal-title":"Transpl Cell Ther"},{"key":"3044_CR50","doi-asserted-by":"crossref","unstructured":"Sumithira Vasu EB, Denlinger N, Szuminski N, Schneider D, Dash P, Wirthlin L, et al. Phase I clinical trial of anti-CD19\/20\/22 chimeric antigen receptor T cells for treatment of relapsed or refractory lymphoid malignancies (Non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, B-prolymphocytic leukemia). Blood. 2022;140:7474\u201375.","DOI":"10.1182\/blood-2022-167340"},{"key":"3044_CR51","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1200\/jco.23.01314","volume":"42","author":"C Rossig","year":"2024","unstructured":"Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, et al. Chimeric antigen receptor (CAR) T-cell products for pediatric cancers: why alternative development paths are needed. J Clin Oncol. 2024;42:253\u20137. https:\/\/doi.org\/10.1200\/jco.23.01314.","journal-title":"J Clin Oncol"},{"key":"3044_CR52","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.7326\/M22-2276","volume":"176","author":"AH Kelkar","year":"2023","unstructured":"Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, et al. Second-line chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: a cost-effectiveness analysis. Ann Intern Med. 2023;176:1625\u201337.","journal-title":"Ann Intern Med"},{"key":"3044_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/bioe.13108","volume":"37","author":"SAL van Till","year":"2023","unstructured":"van Till SAL, Smids J, Bunnik EM. Access to effective but expensive treatments: An analysis of the solidarity argument in discussions on funding of medical treatments. Bioethics. 2023;37:111\u20139. https:\/\/doi.org\/10.1111\/bioe.13108.","journal-title":"Bioethics"},{"key":"3044_CR54","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/cts.12666","volume":"12","author":"P Marks","year":"2019","unstructured":"Marks P. The FDA\u2019s regulatory framework for chimeric antigen receptor-T cell therapies. Clin Transl Sci. 2019;12:428\u201330. https:\/\/doi.org\/10.1111\/cts.12666.","journal-title":"Clin Transl Sci"},{"key":"3044_CR55","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/jco.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37:2105\u201319. https:\/\/doi.org\/10.1200\/jco.18.02079.","journal-title":"J Clin Oncol"},{"key":"3044_CR56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bulcan.2025.11.010","volume":"113","author":"C-A Brug\u00e8re","year":"2025","unstructured":"Brug\u00e8re C-A, Deschaseaux P, Gomez E, Roffiaen C, Brigand T, Esposito G, et al. Estimating the real price of CAR-T cells in France: From list price to net price. Bull du Cancer. 2025;113:113\u201320.","journal-title":"Bull du Cancer"},{"key":"3044_CR57","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","volume":"36","author":"A Gajra","year":"2022","unstructured":"Gajra A, Zalenski A, Sannareddy A, Jeune-Smith Y, Kapinos K, Kansagra A. Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice. Pharm Med. 2022;36:163\u201371. https:\/\/doi.org\/10.1007\/s40290-022-00428-w.","journal-title":"Pharm Med"},{"key":"3044_CR58","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1002\/ijc.33156","volume":"147","author":"T Ran","year":"2020","unstructured":"Ran T, Eichm\u00fcller SB, Schmidt P, Schlander M. Cost of decentralized CAR T-cell production in an academic nonprofit setting. Int J Cancer. 2020;147:3438\u201345. https:\/\/doi.org\/10.1002\/ijc.33156.","journal-title":"Int J Cancer"},{"key":"3044_CR59","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1182\/bloodadvances.2025017298","volume":"9","author":"S Rives","year":"2025","unstructured":"Rives S. Point-of-care CAR T-cell therapy: toward broader access. Blood Adv. 2025;9:5103\u20134. https:\/\/doi.org\/10.1182\/bloodadvances.2025017298.","journal-title":"Blood Adv"},{"key":"3044_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200977","volume":"33","author":"HK Palani","year":"2025","unstructured":"Palani HK, Arunachalam AK, Kulkarni U, Yasar M, Venkatraman A, Palanikumar S, et al. Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial. Mol Ther Oncol. 2025;33:200977. https:\/\/doi.org\/10.1016\/j.omton.2025.200977.","journal-title":"Mol Ther Oncol"},{"key":"3044_CR61","doi-asserted-by":"publisher","first-page":"e786","DOI":"10.1016\/s2352-3026(22)00226-5","volume":"9","author":"N Gagelmann","year":"2022","unstructured":"Gagelmann N, Sureda A, Montoto S, Murray J, Bola\u00f1os N, Kenyon M, et al. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. Lancet Haematol. 2022;9:e786\u2013e795. https:\/\/doi.org\/10.1016\/s2352-3026(22)00226-5.","journal-title":"Lancet Haematol"},{"key":"3044_CR62","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jval.2024.04.004","volume":"27","author":"K Thavorn","year":"2024","unstructured":"Thavorn K, Thompson ER, Kumar S, Heiskanen A, Agarwal A, Atkins H, et al. Economic evaluations of chimeric antigen receptor T-cell therapies for hematologic and solid malignancies: a systematic review. Value Health. 2024;27:1149\u201373. https:\/\/doi.org\/10.1016\/j.jval.2024.04.004.","journal-title":"Value Health"},{"key":"3044_CR63","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jcyt.2020.08.007","volume":"23","author":"C Lam","year":"2021","unstructured":"Lam C, Meinert E, Yang A, Cui Z. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation. Cytotherapy. 2021;23:433\u201351. https:\/\/doi.org\/10.1016\/j.jcyt.2020.08.007.","journal-title":"Cytotherapy"},{"key":"3044_CR64","unstructured":"European Medicines Agency. (2025). PRIME: Priority medicines. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/prime-priority-medicines"},{"key":"3044_CR65","doi-asserted-by":"publisher","first-page":"e686","DOI":"10.1016\/S2352-3026(21)00279-9","volume":"8","author":"S Nagai","year":"2021","unstructured":"Nagai S. Regulatory hurdles for CAR T-cell therapy in Japan. Lancet Haematol. 2021;8:e686\u2013e687. https:\/\/doi.org\/10.1016\/S2352-3026(21)00279-9.","journal-title":"Lancet Haematol"},{"key":"3044_CR66","unstructured":"CAR T Vision Steering Committee. Executive summary: Expanding availability of CAR T-cell therapy. 2025. https:\/\/cartvision.com\/executive-summary\/"},{"key":"3044_CR67","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124\u201332. https:\/\/doi.org\/10.1038\/s41591-022-02017-5.","journal-title":"Nat Med"},{"key":"3044_CR68","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1182\/blood-2024-204300","volume":"144","author":"A Barz Leahy","year":"2024","unstructured":"Barz Leahy A, Brogdon J, Cain L, Dinofia AM, Fraietta JA, Hanna R, et al. Cost-effective manufacture and promising initial efficacy of huCART19 cells manufactured using the clinimacs prodigy platform. Blood. 2024;144:3470\u20133470. https:\/\/doi.org\/10.1182\/blood-2024-204300.","journal-title":"Blood"},{"key":"3044_CR69","doi-asserted-by":"publisher","unstructured":"Brazil\u2019s low-cost CAR-Ts take on Global South. Nat Biotechnol 2025;43:657\u2013657. https:\/\/doi.org\/10.1038\/s41587-025-02691-z.","DOI":"10.1038\/s41587-025-02691-z"},{"key":"3044_CR70","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","volume":"58","author":"HK Palani","year":"2023","unstructured":"Palani HK, Arunachalam AK, Yasar M, Venkatraman A, Kulkarni U, Lionel SA, et al. Decentralized manufacturing of anti-CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India. Bone Marrow Transpl. 2023;58:160\u20137. https:\/\/doi.org\/10.1038\/s41409-022-01866-5.","journal-title":"Bone Marrow Transpl"},{"key":"3044_CR71","doi-asserted-by":"publisher","first-page":"e3070","DOI":"10.7196\/SAMJ.2025.v115i5.3070","volume":"115","author":"C Hendricks","year":"2025","unstructured":"Hendricks C, Viljoen I, Botes M, Brittain D, Mahlangu J, Verburgh E, et al. Progress in advanced cellular and gene therapies in South Africa and barriers to patient access: a National Consortium paper on behalf of the BloodSA Cell and Gene Therapy working party. South Afr Med J. 2025;115:e3070 https:\/\/doi.org\/10.7196\/SAMJ.2025.v115i5.3070.","journal-title":"South Afr Med J"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03044-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:23:19Z","timestamp":1790245399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03044-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":71,"alternative-id":["3044"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03044-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"4 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UG, Advisory: Kite, BMS, Autolus, Kyverna. HTG: speakers bureau and participation in Ad boards: Gilead. JK, COI: receives funding from Miltenyi Biotech, Novartis. Inventor on multiple patents dealing with CART engineering en gdTCR. Shareholder of Gadeta BV founders. JK is an inventor on multiple patents dealing with engineered immune cells, is shareholder of Gadeta founders BV, and receives funding from Miltenyi Biotec and Novartis. JAS: consultancy for BMS, Vertex, and Jazz in last 36 months. MDL: Research collaboration with Miltenyi Biotec and Caring Cross; Chief Medical Officer, Kure Cells. MA: travel grants from Gilead. REF: travel grants and speakers bureau AZ, Roche, J&J, Novartis, BeiGene, Gilead, BMS, MSD, AbbVie, Pfizer, Sanofi, Takeda, Kite. NW: receives speaker\u2019s fees from BMS, Celgene, Johnson & Johnson, Kite, Gilead, Miltenyi Biotec.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}